Melanoma Research Alliance
Imaging and therapeutic targeting of lymphangiogenesis in melanoma
by
Monica Langfritz-Gütermann
A main limitation for rational drug design in cancer, particularly in melanoma, is the lack of physiologically-relevant models and tracers to monitor metastatic cells in vivo. To overcome these complications we have assembled a team of experts in melanoma progression and drug response, tumor spectroscopy, biological chemistry, dermatology, pathology and oncology.